← Back to search
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
HOUSTON, TX, 77030
Unclaimed
Prime contracting experience
39 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Health Resources and Services Administration | NATIONAL CORD BLOOD INVENTORY | — | $67,006,495 | Sep 10, 2026 | Sep 27, 2019 – Sep 3, 2036 |
| Prime | Department of Health and Human Services National Institutes of Health | OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | — | $1,578,579 | Aug 31, 2026 | Sep 1, 2026 – Aug 31, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | BORDETELLA-FREE BABOONS FOR PERTUSSIS INFECTION AND VACCINATION STUDIES | — | $368,627 | Aug 31, 2026 | Aug 31, 2026 – Aug 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC) | 75N91024D00004USAspending | $1,324,125 | Aug 10, 2026 | Sep 25, 2025 – Mar 24, 2028 |
| Prime | Department of Health and Human Services Food and Drug Administration | BAA FY26C1FP7 MD ANDERSON ONCOLOGY CENTER FOR EXCELLENCE (OCE), EVALUATING BAYESIAN EFFECTIVE SAMPLE SIZE AND DECISION CRITERIA FOR PEDIATRIC AND RARE DISEASE TRIALS | — | $752,304 | Aug 6, 2026 | Sep 30, 2026 – Sep 29, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | — | $8,683,558 | Jul 30, 2026 | Dec 1, 2020 – Aug 31, 2026 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | MED PHYSICS PEER REVIEW SERVICES | — | $1,147,040 | Jul 14, 2026 | Sep 30, 2024 – Sep 29, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION | 75N91019D00021USAspending | $1,293,012 | May 4, 2026 | Jul 26, 2023 – Dec 25, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER | 75N91019D00021USAspending | $1,121,090 | Apr 28, 2026 | Jun 1, 2022 – May 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | 75N91019D00021USAspending | $1,097,981 | Apr 8, 2026 | Sep 15, 2022 – Jun 14, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA | 75N91019D00021USAspending | $1,249,115 | Mar 9, 2026 | Jun 26, 2023 – Oct 25, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION | 75N91024D00004USAspending | $551,730 | Feb 11, 2026 | Sep 20, 2024 – Dec 19, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE | 75N91019D00021USAspending | $930,247 | Nov 20, 2025 | Sep 16, 2021 – Mar 15, 2025 |
| Prime | Department of Health and Human Services Food and Drug Administration | BAA-MD ANDERSON-STATISTICAL DESIGNS AND CONSIDERATIONS FOR DOSE OPTIMIZATION FY25C1FP6 | — | $1,184,156 | Sep 30, 2025 | Sep 16, 2025 – Sep 29, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER | 75N91019D00021USAspending | $1,272,481 | Jun 30, 2025 | Sep 15, 2023 – Mar 14, 2027 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | MEDICAL PHYSICS PEER REVIEW OF RADIATION THERAPY QUALITY ASSURANCE OPERATIONS | — | $972,225 | Jun 11, 2025 | Sep 30, 2021 – Mar 12, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | 75N91019D00021USAspending | $840,820 | Jun 2, 2025 | Jun 1, 2020 – May 31, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS | 75N91019D00021USAspending | $1,162,922 | Apr 30, 2025 | Sep 16, 2021 – Mar 15, 2025 |
| Prime | Department of Health and Human Services Food and Drug Administration | IMMUNOGENICITY STUDY IN BABOONS FOLLOWING VACCINATION WITH EXPERIMENTAL ACELLULAR PERTUSSIS VACCINES. | — | $425,645 | Apr 21, 2025 | Sep 28, 2021 – Mar 27, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER | HHSN261201200034IUSAspending | $556,189 | Dec 13, 2024 | Sep 1, 2017 – Apr 30, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL | HHSN261201200034IUSAspending | $1,581,195 | Dec 12, 2024 | Aug 1, 2015 – Jul 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 4-HYDROXYTAMOXIFEN TOPICAL GEL IN WOMEN WITH MAMMOGRAPHICALLY DENSE BREASTS | HHSN261201200034IUSAspending | $2,186,265 | Dec 12, 2024 | Sep 19, 2016 – Sep 18, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | BIOMEDICAL (BASIC) | — | $4,878,741 | Nov 13, 2024 | Aug 10, 2009 – Sep 13, 2017 |
| Prime | Department of Health and Human Services National Institutes of Health | OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH | HHSN261201200034IUSAspending | $2,048,502 | Jun 27, 2024 | Sep 10, 2019 – Sep 22, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST | HHSN261201200034IUSAspending | $501,636 | May 9, 2024 | Sep 15, 2015 – May 9, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | CANCER PREVENTION BY VACCINATION AGAINST INDUCED ANTIGENS | 75N91019D00021USAspending | $1,219,900 | Nov 21, 2023 | Sep 15, 2019 – Jun 14, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | REPURPOSING OF MACROLIDE ANTIBIOTIC CLARITHROMYCIN FOR THE PREVENTION OF LUNG AND BREAST CANCER | 75N91019D00021USAspending | $912,585 | Oct 23, 2023 | Sep 15, 2019 – Sep 14, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION | 75N91019D00021USAspending | $1,191,330 | Jun 6, 2023 | Sep 21, 2020 – Dec 20, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | TARGETING THE RXR PATHWAY FOR THE PREVENTION OF TRIPLE-NEGATIVE BREAST CANCER HHSN2612015000181 TASK ORDER 9 | HHSN261201500018IUSAspending | $774,513 | May 16, 2023 | Sep 17, 2018 – Jun 16, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | RANK LIGAND INHIBITION - A POTENTIAL CHEMOPREVENTION STRATEGY FOR WOMEN AT HIGH GENETIC RISK OF BREAST CANCER HHSN2612015000181 TO: HHSN26100008 PP: 9/17/18 TO 3/16/2021 | HHSN261201500018IUSAspending | $849,016 | May 8, 2023 | Sep 17, 2018 – Dec 16, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT | HHSN261201200034IUSAspending | $4,248,161 | Apr 13, 2023 | Sep 24, 2015 – Sep 23, 2019 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-BASED VACCINE | 75N91019D00021USAspending | $632,712 | Mar 14, 2023 | May 12, 2021 – Feb 11, 2023 |
| Prime | Department of Health and Human Services Food and Drug Administration | STUDY - MODULAR APPLICATION OF SURFACE TECHNOLOGY FOR THE GENERATION OF ANTIGEN-SPECIFIC T CELLS - BAAPMQWP#217 | — | $283,546 | Nov 23, 2022 | Sep 13, 2019 – Sep 15, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | PREVENTION OF HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | HHSN261201500018IUSAspending | $728,679 | Aug 24, 2022 | Jul 20, 2018 – Apr 19, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019 | HHSN261201500018IUSAspending | $979,494 | Aug 23, 2022 | Jun 15, 2017 – Jun 30, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | RHESUS, INDIAN ORIGIN, EVEN GENDER, - 2 YRS OF AGE, SPF IAW RFQ NC42. (75N98021D00018) | 75N98021D00018USAspending | $255,965 | Jul 16, 2022 | Jul 16, 2022 – Jul 31, 2022 |
| Prime | Department of Health and Human Services Health Resources and Services Administration | TAS::75 0350::TAS - PROVIDE FOR THE COLLECTION AND MAINTENANCE OF GENETICALLY DIVERSE, HIGH-QUALITY UMBILICAL CORD BLOOD UNITS FOR INCLUSION IN THE NATIONAL CORD BLLOD INVENTORY | — | $30,351,425 | Apr 21, 2022 | Sep 8, 2010 – Sep 24, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF PILOT STUDY OF DENOSUMAB IN BRCA1/2 MUTATION CARRIERS SCHEDULED FOR RISK-REDUCING SALPINGO-OOPHERECTOMY | HHSN261201200034IUSAspending | $262,986 | Mar 17, 2022 | Sep 21, 2017 – Dec 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF BREAST CANCER | HHSN261201500018IUSAspending | $714,124 | Feb 24, 2022 | Sep 15, 2017 – Dec 31, 2020 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
7 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | AGREEMENT: $120,870
AMD 1: -$84,279
THE CONTRACTOR SHALL IDENTIFY ALL PROTON TREATED PEDIATRIC PATIENTS AND ALL PHOTON TREATED PEDIATRIC CANCER PATIENTS AT ITS INSTITUTION. FOR ALL PATIENTS MEETING INCLUSION CRITERIA, THE CONTRACTOR WILL RETRIEVE REQUIRED DATA ELEMENTS FROM EXISTING MEDIAL RECORDS AND END DATA ELEMENTS (NOT TO INCLUDE PERSONAL IDENTIFIERS) INTO A SECURE DATA COLLECTION TOOL DEVELOPED BY THE PEDIATRIC PROTON CONSORTIUM REGISTRY (PPCR) TEAM AT THE COORDINATING CENTER FOR DATA COLLECTION. THE CONTRACTOR SHALL LOCATE RADIOTHERAPY AND IMAGING DATA FROM ELIGIBLE PROTON OR PHOTON-TREATED PEDIATRIC PATIENTS, DE-IDENTIFY AS NECESSARY, AND UPLOAD THE DE-IDENTIFIED DATA TO AN ONLINE IMAGING FILE REPOSITORY MAINTAINED BY THE PPCR TEAM AT THE COORDINATING CENTER. P700000723 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541990 Parent award performance state: TX Parent award description: US PEDIATRIC PROTON AND PHOTON THERAPY COHORT AWARD View parent award on USAspending | — | $36,591 | Jun 18, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | MD ANDERSON CANCER CENTER WILL ACT AS A CLINICAL SITE, ENROLLING AND FOLLOWING SUBJECTS IN THE STUDY PROTOCOL. THE SUBCONTRACT INCLUDES EFFORT OF DR. ROY CHEMALY AND THE STUDY COORDINATOR AS COST-REIMBURSEABLE COMPONENTS. THE TOTAL AMOUNT PAID FOR PER SUBJECT MILESTONE PAYMENTS WILL VARY, DEPENDENT ON THE ACTUAL NUMBER OF SUBJECTS ENROLLED AND THE NUMBER OF STUDY VISITS COMPLETED. DR CHEMALY IS AN ATTENDING PHYSICIAN IN THE INFECTIOUS DISEASE SERVICE OF THE CLINICAL RESEARCH PROGRAM OF ANTI-INFECTIVES AT MD ANDERSON CANCER CENTER. DR CHEMALY WILL BE RESPONSIBLE FOR THE CONDUCT OF
THE STUDY AT MD ANDERSON CANCER CENTER. THE STUDY COORDINATOR WILL BE RESPONSIBLE FOR ENSURING SUBJECT ACCRUAL, COMPLIANCE WITH STUDY PROCEDURES AND OVERSIGHT OF REGULATORY REQUIREMENTS FOR THE STUDY. 0001135971 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: WA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $15,604 | Sep 23, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | MD ANDERSON CANCER CENTER WILL ACT AS A CLINICAL SITE, ENROLLING AND FOLLOWING SUBJECTS IN THE STUDY PROTOCOL. THE SUBCONTRACT INCLUDES EFFORT OF DR. ROY CHEMALY AND THE STUDY COORDINATOR AS COST-REIMBURSEABLE COMPONENTS. THE TOTAL AMOUNT PAID FOR PER SUBJECT MILESTONE PAYMENTS WILL VARY, DEPENDENT ON THE ACTUAL NUMBER OF SUBJECTS ENROLLED AND THE NUMBER OF STUDY VISITS COMPLETED. DR CHEMALY IS AN ATTENDING PHYSICIAN IN THE INFECTIOUS DISEASE SERVICE OF THE CLINICAL RESEARCH PROGRAM OF ANTI-INFECTIVES AT MD ANDERSON CANCER CENTER. DR CHEMALY WILL BE RESPONSIBLE FOR THE CONDUCT OF
THE STUDY AT MD ANDERSON CANCER CENTER. THE STUDY COORDINATOR WILL BE RESPONSIBLE FOR ENSURING SUBJECT ACCRUAL, COMPLIANCE WITH STUDY PROCEDURES AND OVERSIGHT OF REGULATORY REQUIREMENTS FOR THE STUDY. 0001135971 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: WA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $16,712 | Oct 27, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | MD ANDERSON CANCER CENTER WILL ACT AS A CLINICAL SITE, ENROLLING AND FOLLOWING SUBJECTS IN THE STUDY PROTOCOL. THE SUBCONTRACT INCLUDES EFFORT OF DR. ROY CHEMALY AND THE STUDY COORDINATOR AS COST-REIMBURSEABLE COMPONENTS. THE TOTAL AMOUNT PAID FOR PER SUBJECT MILESTONE PAYMENTS WILL VARY, DEPENDENT ON THE ACTUAL NUMBER OF SUBJECTS ENROLLED AND THE NUMBER OF STUDY VISITS COMPLETED. DR CHEMALY IS AN ATTENDING PHYSICIAN IN THE INFECTIOUS DISEASE SERVICE OF THE CLINICAL RESEARCH PROGRAM OF ANTI-INFECTIVES AT MD ANDERSON CANCER CENTER. DR CHEMALY WILL BE RESPONSIBLE FOR THE CONDUCT OF
THE STUDY AT MD ANDERSON CANCER CENTER. THE STUDY COORDINATOR WILL BE RESPONSIBLE FOR ENSURING SUBJECT ACCRUAL, COMPLIANCE WITH STUDY PROCEDURES AND OVERSIGHT OF REGULATORY REQUIREMENTS FOR THE STUDY. 0001135971 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: WA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $84,269 | May 3, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | MD ANDERSON CANCER CENTER WILL ACT AS A CLINICAL SITE, ENROLLING AND FOLLOWING SUBJECTS IN THE STUDY PROTOCOL. THE SUBCONTRACT INCLUDES EFFORT OF DR. ROY CHEMALY AND THE STUDY COORDINATOR AS COST-REIMBURSEABLE COMPONENTS. THE TOTAL AMOUNT PAID FOR PER SUBJECT MILESTONE PAYMENTS WILL VARY, DEPENDENT ON THE ACTUAL NUMBER OF SUBJECTS ENROLLED AND THE NUMBER OF STUDY VISITS COMPLETED. DR CHEMALY IS AN ATTENDING PHYSICIAN IN THE INFECTIOUS DISEASE SERVICE OF THE CLINICAL RESEARCH PROGRAM OF ANTI-INFECTIVES AT MD ANDERSON CANCER CENTER. DR CHEMALY WILL BE RESPONSIBLE FOR THE CONDUCT OF
THE STUDY AT MD ANDERSON CANCER CENTER. THE STUDY COORDINATOR WILL BE RESPONSIBLE FOR ENSURING SUBJECT ACCRUAL, COMPLIANCE WITH STUDY PROCEDURES AND OVERSIGHT OF REGULATORY REQUIREMENTS FOR THE STUDY. 0001135971 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: WA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $115,488 | Apr 17, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THIS TASK ORDER WILL CONSIST OF THREE SEPARATE ARMS OF RESEARCH. THE SUBCONTRACTOR WILL OVERSEE THE ANIMAL WORK ASSOCIATED WITH THIS TASK ORDER TO INCLUDE RESEARCH-RELATED MANIPULATIONS, SAMPLE COLLECTION, ANIMAL HUSBANDRY, AND VETERINARY OBSERVATION/CARE. TUL-HSC-560500-22/23 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: LA Parent award description: CONDUCT STUDY P217 View parent award on USAspending | 75N93020D00007USAspending | $1,369,225 | Jan 31, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | MD ANDERSON CANCER CENTER WILL ACT AS A CLINICAL SITE, ENROLLING AND FOLLOWING SUBJECTS IN THE STUDY PROTOCOL. THE SUBCONTRACT INCLUDES EFFORT OF DR. ROY CHEMALY AND THE STUDY COORDINATOR AS COST-REIMBURSEABLE COMPONENTS. THE TOTAL AMOUNT PAID FOR PER SUBJECT MILESTONE PAYMENTS WILL VARY, DEPENDENT ON THE ACTUAL NUMBER OF SUBJECTS ENROLLED AND THE NUMBER OF STUDY VISITS COMPLETED. DR CHEMALY IS AN ATTENDING PHYSICIAN IN THE INFECTIOUS DISEASE SERVICE OF THE CLINICAL RESEARCH PROGRAM OF ANTI-INFECTIVES AT MD ANDERSON CANCER CENTER. DR CHEMALY WILL BE RESPONSIBLE FOR THE CONDUCT OF THE STUDY AT MD ANDERSON CANCER CENTER. THE STUDY COORDINATOR WILL BE RESPONSIBLE FOR ENSURING SUBJECT ACCRUAL, COMPLIANCE WITH STUDY PROCEDURES AND OVERSIGHT OF REGULATORY REQUIREMENTS FOR THE STUDY. 0001057625 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: WA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $141,360 | Jul 20, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Veterans AffairsGov-sourced
- Department of Health and Human ServicesGov-sourced